An interventional study of KI-362-US1 (YP2.2VM) in Aphakia, Postcataract, sponsored by Kowa Research Institute, Inc.. Recruiting at 9 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to evaluate how well an artificial lens, called an intraocular lens (IOL), performs in adults undergoing cataract surgery. During cataract surgery, the eye's natural lens is removed and replaced with an artificial lens to improve vision.
The main goal of the study is to evaluate participants' vision after the IOL is placed in the eye. Approximately one year after surgery, participants' vision will be assessed to determine how clearly they can see.
The results of this study will provide additional information about the performance of the IOL in adults undergoing cataract surgery.
Kowa Research Institute, Inc. is the lead sponsor of 47 studies on the registry; 1 is open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 9 (45%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive an intraocular lens (IOL) implanted during cataract surgery to replace the natural lens of the eye. The IOL is delivered using a single-use, preloaded delivery device and positioned within the eye's natural lens capsule.
Device: KI-362-US1 (YP2.2VM)
Injector and one-piece (1P) monofocal IOL
Proportion of Participants Achieving a Predefined BCDVA Criterion at Visit 5
Proportion of participants achieving a predefined best-corrected distance visual acuity (BCDVA) criterion, as measured using Early Treatment Diabetic Retinopathy Study (ETDRS) illuminated charts at postoperative days 330-390 (Visit 5, Form 5).
Time frame: Baseline through Visit 5, approximately Days 330-390.
Proportion of Participants With Selected Ocular Adverse Events
Proportion of participants experiencing one or more predefined ocular adverse events following treatment, including both cumulative and persistent events. Events are assessed based on their occurrence or persistence during the study period.
Time frame: Baseline through end of study (up to 15 months)
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Sep 2027, 11 months after the start.
Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, last on Nov 13, 2026.
Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2028 → Sep 2027, on Nov 6, 2026.
Completion moved once since we started tracking on Sep 25, 2026: Nov 2028 → Sep 2028, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aphakia, Postcataract
Kowa Research Institute, Inc. →